Medical Equipment

Nuclear Medicine Diagnostics Market Growth Expected To Reach $13.76 Billion By 2030 At 11.7% CAGR

April 14, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Nuclear Medicine Diagnostics Market Between 2026 And 2030? _x000D_

The nuclear medicine diagnostics market has experienced rapid expansion in recent years. This market is projected to grow from $7.88 billion in 2025 to $8.84 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.2%. Historically, this growth can be attributed to several factors including the increasing use of radioactive tracers in diagnostics, the expansion of hospital-based nuclear medicine units, a rising demand for functional imaging, the availability of technetium-based radiopharmaceuticals, and the growth of clinical research in nuclear medicine._x000D_

_x000D_

The nuclear medicine diagnostics market size is projected to experience rapid expansion in the coming years. It is expected to grow to $13.77 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This growth during the forecast period can be attributed to increased investments in theranostics, a rising adoption of precision oncology diagnostics, the expansion of PET imaging infrastructure, a growing focus on the development of targeted radiopharmaceuticals, and increasing regulatory support for nuclear diagnostics. Major trends anticipated in the forecast period include a greater adoption of PET-based diagnostic radiopharmaceuticals, an escalating demand for personalized nuclear diagnostics, the growing integration of imaging and therapeutic applications, the expansion of oncology-focused nuclear medicine procedures, and an enhanced focus on short-half-life radiotracers._x000D_

_x000D_

#Access Your Free Sample Report For In-Depth Market Analysis:#_x000D_

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report_x000D_

_x000D_

What Factors Are Contributing To The Growth Of The Nuclear Medicine Diagnostics Market?_x000D_

The expanding occurrence of cancer is projected to boost the expansion of the nuclear medicine diagnostics market in the future. Cancer refers to a collection of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body, potentially forming a mass or tumor. The increased incidence of cancer can be attributed to the aging global populace, as cancer rates rise substantially with age, and enhanced healthcare contributes to longer life expectancies. Nuclear medicine diagnostics plays a crucial role in identifying, staging, and tracking various cancers, employing radioactive materials that specialized cameras can detect to generate detailed images of internal organs and tissue functions. For instance, in May 2025, the National Cancer Institute, a US-based intergovernmental organization, reported that in 2022, close to 20 million individuals received a cancer diagnosis, with 9.7 million deaths, and by 2050, these numbers are expected to surge to 33 million new cases and 18.2 million deaths each year. Consequently, the increasing volume of cancer cases is fueling the growth of the nuclear medicine diagnostics market._x000D_

_x000D_

How Is The Nuclear Medicine Diagnostics Market Organized By Segment Classification?_x000D_

The nuclear medicine diagnostics market covered in this report is segmented – _x000D_

_x000D_

1) By Type: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals_x000D_

2) By Application: Cardiology, Thyroid, Neurology, Oncology, Other Applications_x000D_

3) By End-User: Hospitals And Diagnostic Centers, Research Institutes_x000D_

_x000D_

Subsegments: _x000D_

1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals, Iodine-123-Based Radiopharmaceuticals, Thallium-201-Based Radiopharmaceuticals, Other SPECT Radiopharmaceuticals _x000D_

2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals, Carbon-11-Based Radiopharmaceuticals, Gallium-68-Based Radiopharmaceuticals, Other PET Radiopharmaceuticals _x000D_

_x000D_

What Trends Are Shaping The Future Of The Nuclear Medicine Diagnostics Market?_x000D_

Companies operating prominently within the nuclear medicine diagnostics market are concentrating on introducing sophisticated solutions, such as advanced medical technologies, to gain a competitive advantage. Advanced medical technologies represent cutting-edge innovations in the medical field designed to improve patient outcomes, enhance the quality of care, and promote better health. For instance, in August 2023, Gleneagles Hospital, a Malaysia-based company offering medical and healthcare services, unveiled its Nuclear Medicine Unit. This nuclear medicine unit functions as a specialized department within a hospital or medical center, equipped with state-of-the-art technology and manned by highly skilled professionals. The primary objective of this facility is to offer early detection, diagnosis, and treatment of diseases by utilizing nuclear medicine imaging techniques._x000D_

_x000D_

Who Are The Industry Participants Involved In The Nuclear Medicine Diagnostics Market?_x000D_

Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., Eczacibasi-Monrol Nuclear Products Co. _x000D_

_x000D_

#Get The Full Nuclear Medicine Diagnostics Market Report:#_x000D_

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report_x000D_

_x000D_

Which Region Represents The Largest Share Of The Nuclear Medicine Diagnostics Market?_x000D_

North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request A Customized Nuclear Medicine Diagnostics Market Report For Competitive Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Nuclear Medicine Diagnostics Market 2026, By The Business Research Company#_x000D_

_x000D_

Nuclear Medicine Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report_x000D_

_x000D_

Nuclear Medicine Radioisotopes Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report_x000D_

_x000D_